(2015) Phthalimide analogs as probable 15-lipoxygenase-1 inhibitors: Synthesis, biological evaluation and docking studies. DARU, Journal of Pharmaceutical Sciences.
![]() |
Text
313.pdf Download (1MB) |
Abstract
Background: Recent studies have been explained the role of lipoxygenases (LOX) in the origin of cancer. Among the lipoxygenases, the 5-LOX, 12-LOX and 15-LOX are more important in the cause of neoplastic disorders. In the present investigation, a new series of anticancer agents with 1,3,4-thiadiazole and phthalimide substructures were synthesized and their in vitro cytotoxicity was evaluated by MTT assay. Moreover, enzyme inhibitory potency was also assessed by enzymatic protocol towards 15-LOX-1. Molecular docking was performed to explore in silico binding mode of the target compounds. Results: Tested compounds showed a better cytotoxic activity against HT29 cell line (colorectal cancer) in comparison with other cell lines (PC3: prostate carcinoma; SKNMC: neuroblastoma). Unfortunately, all of the tested derivatives rendered lower inhibitory potency than quercetin towards 15-LOX-1. Four hydrogen bonds were detected in docking studies for compound 4d as the most potent derivative in enzymatic assay. Conclusions: The biological results of reported compounds in this research were not so satisfactory. But, further structural modifications are necessary to improve the bioactivity of these derivatives. © 2015 Aliabadi et al.
Item Type: | Article |
---|---|
Keywords: | 2 (1,3 dioxoisoindolin 2 yl) n (5 mercapto 1,3,4 thiadiazol 2 yl)acetamide; 2 (1,3 dioxoisoindolin 2 yl) n 5 (2 fluorobenzylthio) 1,3,4 thiadiazol 2 ylacetamide; 2 (1,3 dioxoisoindolin 2 yl) n 5 (2 nitrobenzylthio) 1,3,4 thiadiazol 2 ylacetamide; 2 (1,3 dioxoisoindolin 2 yl) n 5 (3 fluorobenzylthio) 1,3,4 thiadiazol 2 ylacetamide; 2 (1,3 dioxoisoindolin 2 yl) n 5 (3 methoxybenzylthio) 1,3,4 thiadiazol 2 ylacetamide; 2 (1,3 dioxoisoindolin 2 yl) n 5 (3 nitrobenzylthio) 1,3,4 thiadiazol 2 ylacetamide; 2 (1,3 dioxoisoindolin 2 yl) n 5 (4 fluorobenzylthio) 1,3,4 thiadiazol 2 ylacetamide; 2 (1,3 dioxoisoindolin 2 yl) n 5 (4 methoxybenzylthio) 1,3,4 thiadiazol 2 ylacetamide; 2 (1,3 dioxoisoindolin 2 yl) n 5 (4 nitrobenzylthio) 1,3,4 thiadiazol 2 ylacetamide; 2 (1,3 dioxoisoindolin 2 yl)acetic acid; arachidonate 15 lipoxygenase; arachidonate 15 lipoxygenase 1; lipoxygenase inhibitor; n 5 (2 chlorobenzylthio) 1,3,4 thiadiazol 2 yl 2 (1,3 dioxoisoindolin 2 yl)acetamide; n 5 (3 chlorobenzylthio) 1,3,4 thiadiazol 2 yl 2 (1,3 dioxoisoindolin 2 yl)acetamide; n 5 (4 chlorobenzylthio) 1,3,4 thiadiazol 2 yl 2 (1,3 dioxoisoindolin 2 yl)acetamide; n 5 (benzylthio) 1,3,4 thiadiazol 2 yl 2 (1,3 dioxoisoindolin 2 yl)acetamide; phthalimide derivative; quercetin; unclassified drug, antineoplastic activity; Article; chemical modification; concentration response; controlled study; drug activity; drug binding; drug cytotoxicity; drug potency; drug structure; drug synthesis; drug targeting; enzymatic assay; enzyme inhibition; HT 29 cell line; human; human cell; hydrogen bond; in vitro study; molecular docking; molecular model; MTT assay; neuroblastoma cell line; PC3 cell line; physical chemistry; prostate cancer cell line; prostate carcinoma; proton nuclear magnetic resonance; SKNMC cell line |
Journal or Publication Title: | DARU, Journal of Pharmaceutical Sciences |
Volume: | 23 |
Number: | 1 |
Publisher: | BioMed Central Ltd. |
Depositing User: | ms soheila Bazm |
URI: | http://eprints.ssu.ac.ir/id/eprint/9241 |
Actions (login required)
![]() |
View Item |